

DZIF

PROGRAMME

24 - 26 November 2016
Flora, Cologne

DZIF Annual Meeting
German Center for Infection Research

Conference Chairs:

Prof. Dr. W. Barchet, Bonn
Prof. Dr. J.F. Drexler, Bonn
Dr. J. Rybniker, Cologne
PD Dr. M. Vehreschild, Cologne



www.dzif-annual-meeting2016.de

* ≤95% Adhärenz **PREZISTA® wurde im Februar 2007 von der EMEA zugelassen. **1** Lathouwers E, et al. Week 192 resistance analysis of HIV-1-infected, treatment-naive patients with virological failure in ARTEMIS, poster presented 9th European Workshop on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, Paphos, Cyprus, March 23–25, 2011. Abstract O–07. **2** Orkin C, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med. 2013 Jan;14(1):49–59. **3** Nelson M et al. Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data J Antimicrob Chemother 2010;65(7):1505–09.

PREZISTA® 75 mg/- 150 mg/- 400 mg/- 600 mg/- 800 mg Filmtabletten/- 100 mg/ml Suspension zum Einnehmen. Wirkstoff: Darunavir. **Zusammensetz.:** *Filmtbl.:* 1 Filmtabl. enth. 75 mg, 150 mg, 400 mg, 600 mg bzw. 800 mg Darunavir (als Ethanolat). Sonst. Bestandt.: Jede Tabl. enth. 0,834 mg (400 mg Tabl.) bzw. 2,750 mg (600 mg Tabl.) Gelborange S (E110), mikrokristall. Cellulose, hochdisperses Siliciumdioxid, Crospovidon, Magnesiumstearat, Hypromellose (800 mg Tabl.), Polyvinylalkohol - teilhydrolysiert, Macrogol 3350, Titandioxid (E171), Talkum. ***Suspension:*** Jeder ml d. Susp. enth. 100 mg Darunavir (als Ethanolat). Sonst. Bestandt.: Hyprolose, mikrokrist. Cellulose, Carmellose-Natrium, Citronensäure-Monohydrat, Sucralose, Erdbeer-Sahne-Aroma, maskier. Aroma, Natrium-Methyl-4-hydroxybenzoat (E219) 3,43 mg/ml, Salzsäure (zur pH Wert-Einstellung), ger. Wasser. **Anw.geb.:** Zusammen m. niedrig dosiertem Ritonavir (rtv) in Kombination m. and. antiretrovir. Arzneim. zur Therapie v. Pat. m. Infekt. m. HIV-1. B. antiretroviral nicht vorbeh. Pat. (400 mg, 800 mg, Susp.).B. antiretrov. vorbeh. Erw., einschl. derer, d. mehrf. vorbeh. wurden (75 mg, 150 mg, 400 mg, 600 mg, 800 mg, Susp.). B. pädiatr. Pat. ab 3 J. u. mind. 15 kg KG (75 mg, 150 mg, 600 mg, Susp.) bzw. ab 12 J. u. mind. 40 kg KG (400 mg, 800 mg). Zus. m. Cobicistat in Kombination m. and. antiretrovir. Arzneim. zur Therapie v. erwachs. Pat. m. Infekt. m. HIV 1 (400 mg, 800 mg, Susp.). Dos.empf. s. jew. Fachinfo. **Gegenanz.:** Überempfindl. gg. Darunavir od. ein. sonst. Bestandt.; schw. Leberfunkt.störg. (Child-Pugh-Klasse C). Zutreff. f. Darunavir i. Kombination m. Ritonavir od. Cobicistat: gleichzeitige Anw. v. Rifampicin, Quetiapin, dem Kombinat. präp. Lopinavir/Ritonavir, Johanniskraut u. AM, deren Clearance in hohem Maße v. CYP3A abhängig ist u. bei denen erhöh. Plasmakonz. m. schwerwieg. u./od. lebensbedrohl. Ereign. einhergehen. Zutreff. f. Darunavir + Cobicistat: Anw. m. starken CYP3A4 Induktoren, wie z.B. Carbamazepin, Phenibarbital u. Phenytoin, da diese d. Exposit gg. Darunavir u. Cobicistat reduz. könnten. Wg. Unsicherheiten bzgl. d. Entwicklungsgr. d. Blut-Hirn-Schranke u. d. Leberenzyme b. Menschen ist PREZISTA® m. niedrig dos. Ritonavir nicht b. pädiatr. Pat. unter 3 J. od. weniger als 15 kg KG anzuw. Stillz. **Bes. Warnhinw. u. Vorsichtsmaßn.:** Regelm. Überprüfg. d. virol. Ansprechens empf., b. Fehlen od. Verlust Resistenztest durchführen. B. ART-vorbeh. Pat. m. einer od. mehr. DRV-RAMs od. ≥ 100.000 HIV-1-RNA Kopien/ml im Plasma od. einer CD4+-Zellzahl v. < 100 x 10^6 Zellen/l sollte PREZISTA® in Kombination m. Cobicistat od. niedrig dosiertem Ritonavir nicht angew. werden. Bhdlgs. abbruch b. schweren Hautreakt.; Hautausschlag b. ART-vorbeh. Pat. häufiger b. Komb.therapie m. Raltegravir. Vor u. währ. d. Bhdlg. Laborunters. d. Leberfunkt., insbes. b. Pat. m. chron. Hepatitis, Leberzirrh. od. b. Pat. m. initialer Transaminasenerhöhung. B. neu auftr. Leberfunkt.störg. od. Verschlecht. Unterbrech. od. Abbruch d. Bhdlg. erwägen. Vorsicht b.: leichter od. mäßiger Leberfunkts.störg. (Child-Pugh-Klasse A u. B), chron. Hep. B u. C, Alter über 65 J.; Sulfonamidallerg.; Hämophilie; Schwangersch. nur wenn d. potentielle Nutzen d. potentielle Risiko rechtfertigt; b. Schwang. m. Begleitmedik., die die Darunavirexposition weiter vermindern könnte. Möglichk. e. Immunrekonstitutionssndr.. Über lebensbedrohl. u. tödl. Interakt. wurde b. Pat. berichtet, die m. Colchicin u. starken Inhibit. v. CYP3A4 u. P Glykoprotein bhdlt. wurden. Efavirenz in Komb. m. PREZISTA/Ritonavir 800/100 mg 1x tgl. kann zu suboptimalen Darunavir C_{min} führen, daher b. Komb. m. Efavirenz Dosierung v. PREZISTA/rtv 600/100 mg 2x tgl. B. Wechsel d. pharmakokin. Verstärkers v. Ritonavir zu Cobicistat ist währ. d. ersten zwei Wo. d. Bhdlg. m. Darunavir/Cobicistat Vors. geboten, besond. wenn währ. d. Anw. v. Ritonavir d. Dosier. v. gleichz. angew. Arzneim. titriert od. eingestellt wurden. In diesen Fällen kann eine Dosisred. d. gleichz. angew. Arzneim. notw. sein. B. dialysepflicht. Pat. wurde Cobicistat nicht untersucht. Cobicistat senkt d. geschätzte Creatinin-Clearance durch Hemmung d. tubul. Sekretion. **Nebenwirk.: Erwachs. Pat.: Darunavir/Ritonavir: *Sehr häufig:*** Diarrhö. ***Häufig:*** Kopfschmerz, Erbrechen, Übelkeit, Bauchschm., Alaninaminotransferase erhöht, erhöhte Amylase i. Blut, Hautausschlag (inkl. makulärer, makulopapul., papul., erythemat. u. juckender Ausschlag), Pruritus, Hypertriglycerid., Hypercholesterin., Hyperlipid., Diab. mell., periph. Neuropathie, Schwindel, aufgeblähter Bauch, Dyspepsie, Flatulenz, Asthenie, Ermüdung (Fatigue), Schlaflosigkeit. ***Gelegentlich:*** Myokardinfarkt, Angina pect., im EKG verläng. QT-Intervall, Tachykardie, Thrombozytopenie, Neutropenie, Leukopenie, Anämie, Lethargie, Parästhesie, Hypästhesie, Schläfrigk., konjunkt. Hyperämie, trockenes Auge, Drehschwindel, Dyspnoe, Husten, Epistaxis, Reizungen i. Rachen, Pankreatitis, Gastritis, gastroösophag. Refluxkrankheit, aphtöse Stomatitis, Würgereiz, Mundtrockenh., Aufstoßen, Empfindungsstörung im Mund, abdominelle Beschwerden, Obstipat., erhöhte Lipase, (akutes) Nierenvers., Nephrolithiasis, erhöhtes Kreatinin i. Blut, Proteinurie, Bilirubinurie, Dysurie, Nykturie, Pollakisurie, Angioödem, generalis. Hautausschlag, allerg. Dermatitis, Ekzem, Erythem, Akne, trockene Haut, Nagelpigmentierung, Urtikaria, Hyperhidrose, Nachtschweiß, Alopezie, Myalgie, Osteonekrose, Muskelspasmen, Muskelschwäche, Arthralgie, Extremitätenschmerz., Osteoporose, erhöhte Kreatinin-Phosphokinase i. Blut, Insulinresistenz, Polydipsie, Gicht, Anorexie, Gewichtsabnahme, Gewichtszunahme, Hyperglykämie, Hypertonie, Pyrexie, Thoraxschmerz, periph. Ödem, Hitzegefühl, Reizbark., Schmerz, allg. Unwohlsein, Immunrekonstitutionssyndr., (Arzneimittel-)Überempf.keit, Hepatitis, zytolyt. Hepatitis, Steatosis hepatis, Transaminasen erhöht, Hepatomegalie, Bilirubin im Blut erhöht, alk. Phosph. im Blut erhöht, Gamma-glutamyltransferase erhöht, Aspartataminotransferase erhöht, erekt. Dysfunkt., Gynäkomastie, Depression, Desorientierth., Angstzust., Schlafstörg., anomale Träume, Hypothyreose, TSH-Blutspiegel erhöht, vermind. Appetit, vermehrter Appetit, vermind. HDL, Lactatdehydrogenase im Blut erhöht, Alpträume, vermind. Libido, Herpes simplex, Dysgeusie, Aufmerksamkeitsstörg., Einschränkg. d. Gedächtnisleistung, Erröten. ***Selten:*** Eosinophilie, muskuloskelettale Steifheit, Arthritis, Gelenksteifigkeit, Erythema multiforme, DRESS, Stevens-Johnson-Syndrom, Dermatitis, seborrh. Dermatitis, Hautläsionen, Xerodermie, Verwirrth.zust., Stimmungsveränd., Unruhe, Synkope, Krampfanfall, Ageusie, Storg. d. Schlafrhythm., Sehstörg., akuter Myokardinfarkt, Sinusbradykardie, Palpitationen, Rhinorrhö, Stomatitis, Hämatemesis, Cheilitis, trock. Lippen, belegte Zunge, vermid. renale Kreatinin-Clearance, Schüttelfrost, anomales Gefühl, Xerosis. ***Nicht bekannt:*** Toxisch Epidermale Nekrolyse, generalis. exanthemat. Pustulose. **Erwachs. Pat.: Darunavir/Cobicistat: *Sehr häufig:*** Kopfschm., Diarrhö, Übelk., Hautausschlag (inkl. makul., makulopapulär. papul., erythem., juckend., general. Ausschlag u. allerg. Dermat.). ***Häufig:*** Überemp., Anorexie, Diabetes mell., Hypercholesterin., Hypertriglycerid., Hyperlipid., anomale Träume, Erbr., Bauchschm., aufgebläh. Bauch, Dyspepsie, Flatulenz, Pankreasenzyme erhöht, Leberenzym. erhöht Angioödem, Pruritus, Urtikaria, Myalgie, Osteonekrose*, Ermüdung, Serumkreatinin erhöht. ***Gelegentlich:*** Immunrekonstitutionssyndr., akute Pankreatitis, Hepatitis*, zytolyt. Hepatitis*, Gynäkomastie*, Asthenie. ***Selten:*** DRESS*, Steven-Johnson-Syndr.* ***Nicht bekannt:*** Tox. epiderm. Nekrolyse*, akute general. exanthemat. Pustulose*. *: D. Nebenwirk. wurden nicht b. klin. Stud. m. Darunavir/Cobicistat berichtet, aber bei d. Bhdlg. mit Darunavir/Ritonavir beob., so dass sie auch m. Darunavir/Cobicistat erwartet werd. können. **Zusätzl. b. antiretrov. Komb. therapie:** Stoffwechselstörg. **(insbes. m. NRTIs):** Myositis, Myalgie, CPK-Wert-Erhöhung, selten Rhabdomyolyse. Berichte v. Spontanblutg. b. Hämophilie-Pat. **Pädiatr. Pat.:** Sicherheitsdaten v. Phase-II-Studien zeigten b. pädiatr. Pat. ein vergleichb. Sicherheitsprofil m. dem d. Erwachs.population. ***Filmtbl.:*** Enth. Gelborange S (E110) (nur 400 mg, 600 mg), das allerg. Reakt. hervorr. kann. ***Suspension:*** Enth. Natrium-Methyl-4-hydroxybenzoat, was allerg. Reakt. auslösen kann (manchm. verzögert). Verschreibungspflichtig. **Pharmaz. Unternehmer:** Janssen-Cilag International NV, 2340 Beerse, Belgien. **Örtl. Vertreter für Deutschland:** Janssen-Cilag GmbH, Johnson & Johnson Platz 1, 41470 Neuss. **Stand d. Inform.:** 01/16.

janssen
PHARMACEUTICAL COMPANIES OF Johnson&Johnson

TABLE OF CONTENTS

Imprint

Conference Director and responsible for editorial content

Dr. Timo Jäger
Deutsches Zentrum für Infektionsforschung e.V.
Inhoffenstraße 7
38124 Braunschweig, Germany

Design and Layout

COCSMEDIA

COCS media GmbH
Rosenheimer Str. 145c
81671 Munich, Germany
www.cocs-media.de

COCS media does not guarantee the correctness of information.

Dear colleagues,

We would like to cordially invite you to this year's German Center for Infection Research Annual Meeting in Cologne.

Ebola and Zika viruses, dangerous hospital pathogens and extensively resistant tuberculosis bacteria have recently drastically demonstrated the kind of global challenges infection research has been confronted with over and over again.
The German Center for Infection Research (DZIF) has been taking up these challenges since 2012, and has compiled a programme for the 2016 Annual Meeting that does justice to the various topics of research.

All nine DZIF research fields (TTUs) will present their current findings and research highlights in a session each. For the first time, Academy scholarship holders will give talks to close each session. The DZIF Academy's declared goal is to educate and train the next generation of infection researchers and to continuously expand its programme. Besides this, the DZIF infrastructures that benefit all the research fields will be presented at the TI-Forum. As in previous years, an extensive poster exhibition will accompany the Annual Meeting's programme.

Lectures, discussions and the poster exhibition all provide opportunities for intensive information exchange which can be continued at the social evening in the Brauhaus Sion. Use this meeting to strengthen your network with colleagues from the other partner sites. The DZIF thrives through collaboration.

We would look forward to welcoming you in Cologne from 24 to 26 November 2016.

Best regards,

Your Conference Chairs

Prof. Dr.
Winfried Barchet

Prof. Dr.
Jan Felix Drexler

Dr.
Jan Rybniker

PD Dr.
Maria Vehreschild

Conference Chairs

Prof. Dr. Winfried Barchet, Bonn
Universitätsklinikum Bonn
Institut für Klinische Chemie und
Klinische Pharmakologie

Prof. Dr. Jan Felix Drexler, Bonn
Universität Bonn
Institut für Virologie

Dr. Jan Rybniker, Cologne
Universitätsklinikum Cologne
Klinik I für Innere Medizin

PD Dr. Maria Vehreschild, Cologne
Universitätsklinikum Cologne
Klinik I für Innere Medizin

Scientific Committee

Prof. Dr. Gerd Fätkenheuer, Cologne
Universitätsklinikum Cologne
Klinik I für Innere Medizin

Prof. Dr. Achim Hörauf, Bonn
Universitätsklinikum Bonn
Institut für medizinische Mikrobiologie,
Immunologie und Parasitologie (IMMIP)

Prof. Dr. Martin Krönke, Cologne
Universitätsklinikum Cologne
Institut für medizinische Mikrobiologie,
Immunologie und Hygiene

Prof. Dr. Hans-Georg Sahl, Bonn
Universitätsklinikum Bonn
Institut für medizinische Mikrobiologie,
Immunologie und Parasitologie (IMMIP)

Organizing Committee

Dr. Anna Albers, Bonn
Universitätsklinikum Bonn

Dr. Timo Jäger, Braunschweig
DZIF e.V.

Gisela Kremer, Cologne
Universitätsklinikum Cologne

Dr. Viktoria Linne, Cologne
Universitätsklinikum Cologne

Dr. Carolynne Schwarze-Zander, Bonn
Universitätsklinikum Bonn

Thursday, 24 November 2016

12:30 - 14:00	Registration & Snacks	
14:00 - 14:10	Welcome	S.08
14:10 - 14:40	**Invited Lecture 1: Sibylle Matz** "New antiinfectives: EU regulations and DZIF-BfArM cooperation"	S.08
14:40 - 15:40	**TTU HIV**	S.08
15:40 - 16:10	Coffee Break	
16:10 - 17:10	**Poster Session**	S.09
17:10 - 18:10	**TTU Hepatitis**	S.09
20:00	Social Evening at Brauhaus Sion	S.09

Friday, 25 November 2016

09:00 - 10:00	**TTU Healthcare-associated and Antibiotic-resistant bacterial Infections**	S.10
10:00 - 10:30	Coffee Break	
10:30 - 11:30	**TTU Gastrointestinal Infections**	S.10
11:30 - 12:30	**TTU Infections of the immunocompromised Host**	S.11
12:30 - 13:30	Lunch Break **Lunchsymposium** S.12 MSD SHARP & DOHME GMBH	
13:30 - 14:30	**Poster Session**	S.12
14:30 - 15:00	**Invited Lecture 2: Seamus O'Brien** "New Antibiotics – Pathways to registration"	S.12
15:00 - 16:00	**TTU Tuberculosis**	S.12
16:00 - 16:30	Coffee Break	
16:30 - 17:30	**TTU Malaria**	S.13
17:30 - 17:40	**DZIF Poster Awards**	S.14
17:40 - 18:10	**DZIF Award Lecture**	S.14
18:10 - 19:10	Get Together with Wine and Cheese	S.14

SCIENTIFIC PROGRAMME – PROGRAMME AT A GLANCE

Saturday, 26 November 2016

09:00 - 10:00	**TTU Emerging Infections**	S.15
10:00 - 10:30	Coffee Break	
10:30 - 11:00	**Invited Lecture 3: Stephen Ward** "The critical importance of screen validation in drug discovery: The search for a new macrofilaricide"	S.15
11:00 - 12:00	**TTU Novel Antiinfectives**	S.16
12:00 - 12:10	Closing Remarks	S.16

TTU = Thematic Translational Unit

Rooms and Location

Scientific Programme and Poster = Festsaal
Lunchsymposium= Parksalon (2nd Level)
Coffee Break and Lunch = Bistro/Orangerie

ST = Short Talk, AT = Academy Talk

14:00 – 14:10 **Welcome**

Festsaal

14:10 – 14:40 **Invited Lecture 1**

Festsaal

14:10 **New antiinfectives: EU regulations and DZIF-BfArM cooperation**
S. Matz, Bonn

14:40 – 15:40 **TTU HIV**

Festsaal *Chairs: C. Lehmann, Cologne*
J. Schulze zur Wiesch, Hamburg

14:40
TTU Lecture 1 **Anti-HIV-1 antibody 10-1074 reduces viremia in HIV-1-infected individuals**
H. Gruell, Cologne

15:00
ST 1 **Translational Platform HIV: Implementation of the Primary HIV Cohort**
M. Stecher, Cologne

15:10
ST 2 **Compartment-specific distribution of human intestinal innate lymphoid cells is altered in HIV patients under effective therapy**
J. Nattermann, Bonn

15:20
ST 3 **Operational evaluation of HIV Point of Care Tests for very early infant HIV diagnostics in infants born from HIV infected mothers in Mbeya, Tanzania**
I. Sabi, Mbeya (Tanzania)

15:30
AT 1 **Human Immunodeficiency Virus (HIV)-1 and its Integration sites in Viral Latency**
W. Wang, Heidelberg

15:40 – 16:10 **Coffee Break**

SCIENTIFIC PROGRAMME
THURSDAY, 24 NOVEMBER 2016

16:10 – 17:10 **Poster Session**

Festsaal For further information please see page 17.

17:10 – 18:10 **TTU Hepatitis**

Festsaal *Chairs: S. Ciesek, Essen*
J. Nattermann, Bonn

17:10
TTU Lecture 2 **Functional characterization of HBV-specific T cell receptors for redirection of T cells against HBV infected hepatocytes**
K. Wisskirchen, Munich

17:30
ST 4 **A proof-of-concept Phase IIa clinical trial to treat chronic HBV/HDV with the entry inhibitor myrcludex B**
S. Urban, Heidelberg

17:40
ST 5 **Identification of host cell requirements and antiviral target for hepatitis D virus infection**
B. Buchmann, Hanover

17:50
ST 6 **Concerted harmonization efforts of HBV cccDNA quantification**
L. Allweiss, Hamburg

18:00
AT 2 **Profile of viral, biochemical and non-invasive fibrosis markers in a cohort of inactive European hepatitis B (HBV) carriers: 3 years follow-up of a prospective longitudinal study (ALBATROS Study)**
V. Knop, Frankfurt am Main

20:00 **Social Evening at Brauhaus Sion**

ST = Short Talk, AT = Academy Talk

09:00 – 10:00	**TTU Healthcare-associated and Antibiotic-resistant bacterial Infections**
Festsaal	*Chairs: M. Vehreschild, Cologne* *M. Willmann, Tübingen*
09:00 TTU Lecture 3	**Human commensals producing a novel antibiotic impair pathogen colonization** *B. Krismer, Tübingen*
09:20 ST 7	**Significant Decrease of Admission Prevalence of 3rd Generation Cephalosporin Resistant Enterobacteriaceae Colonisation in one University Hospital** *A. Rohde, Berlin*
09:30 ST 8	**Comparison between a core-genome MLST scheme and rep-PCR typing schemes to investigate the epidemiology of Klebsiella pneumoniae isolated as part of the CONTAIN study** *P. Higgins, Cologne*
09:40 ST 9	**Genomic landscape of the new colistin resistance gene mcr-1 in Germany** *L. Falgenhauer, Giessen*
09:50 AT 3	**Impact of contact isolation on nosocomial colonization and infection with ESBL-producing Escherichia coli in a high-risk setting – preliminary results from the CONTAIN study** *L. Biehl, Cologne*
10:00 – 10:30	**Coffee Break**
10:30 – 11:30	**TTU Gastrointestinal Infections**
Festsaal	*Chairs: O. Bachmann, Hanover* *M. Schütz, Tübingen*
10:30 TTU Lecture 4	**Engagement of CEACAM receptors by Helicobacter pylori modulates cellulcar responses** *M. Gerhard, Munich*
10:50 ST 10	**Identification of small-molecule inhibitors targeting Cag type IV secretion or respiration in Helicobacter pylori** *F. Schindele, Munich*

SCIENTIFIC PROGRAMME
FRIDAY, 25 NOVEMBER 2016

11:00 ST 11	**Fucosyltransferase-2 Expression in the intestine influences susceptibility to intestinal Salmonella infections** *G. Graßl, Hanover*
11:10 ST 12	**Novel natural compound inhibitors for the New Delhi Metallo-beta-Lactamase 1** *H. Meyer, Munich*
11:20 AT 4	**Screening for a small molecule inhibitor targeting the biogenesis of outer membrane virulence factors in gram-negative Enterobacteriaceae** *J. Schweers, Tübingen*
11:30 – 12:30	**TTU Infections of the immunocompromised Host**
Festsaal	*Chairs: C. Könecke, Hanover* *C. Zielinski, Munich*
11:30 TTU Lecture 5	**Epstein-Barr Viral miRNAs inhibit antiviral T cell responses early in infection** *W. Hammerschmidt, Munich*
11:50 ST 13	**Determining the structure of herpesviral capsid proteins as a basis for rational inhibitor design** *T. Krey, Hanover*
12:00 ST 14	**High-resolution analysis of the CMV-specific T cell receptor repertoire** *A. Mossmann, Munich*
12:10 ST 15	**Tyrosine kinase activity of KSHV thymidine kinase can be targeted by FDA-approved kinase inhibitors to reduce lytic reactivation** *G. Beauclair, Hanover*
12:20 AT 5	**In vitro evaluation of CAR T cells targeted with a high affinity scFv against the HCMV glycoprotein gB** *H. Olbrich, Hanover*
12:30 – 13:30	**Lunch Break**

13:00 – 14:00 **Lunchsymposium MSD**

Parksalon (2nd Level)

Neue antiinfektive Konzepte: From bench to bedside
Chair: M. Vehreschild, Cologne

13:00 **Identifizierung neuer Substanzen: Welche Optionen haben wir?**
T. Schneider, Bonn

13:20 **Anti-Antibiotische Konzepte (Phagen, Probiotika, Antikörper)**
M. Vehreschild, Cologne

13:40 **Der lange Weg zur Entwicklung neuer TB Kombinations-therapien von bench to bed to policy**
M. Hölscher, Munich

This Symposium is organized by MSD SHARP & DOHME GMBH, Munich.

13:30 – 14:30 **Poster Session**

Festsaal For further information please see page 17.

14:30 – 15:00 **Invited Lecture 2**

Festsaal

14:30 **New Antibiotics – Pathways to registration**
S. O'Brien, Macclesfield (United Kingdom)

15:00 – 16:00 **TTU Tuberculosis**

Festsaal *Chairs: A. Rachow, Munich*
J. Rybniker, Cologne

15:00
TTU Lecture 6 **Phenotypic profiling of MTB-specific CD4 T cells allows accurate differentiation between active, treated Tuberculosis (TB) disease and latent infection**
C. Geldmacher, Munich

15:20
ST 16 **Multidrug-resistant Mycobacterium tuberculosis outbreak strains in Gabon**
P. Beckert, Borstel

15:30
ST 17 **Impact of molecular drug resistance testing in multidrug-resistant tuberculosis**
J. Heyckendorf, Borstel

15:40
ST 18 **Lipids are Promising Diagnostic Molecules for Monitoring Antimycobacterial Therapy**
D. Schwudke, Borstel

15:50
AT 6 **M. bovis BCG vaccination induces mycobacteria-specific immune responses but lacks protection from infection of human alveolar macrophages from tuberculosis**
J. Radloff, Borstel

16:00 – 16:30 **Coffee Break**

16:30 – 17:30 **TTU Malaria**

Festsaal *Chairs: B. Mordmüller, Tübingen*
A.-K. Müller, Heidelberg

16:30
TTU Lecture 7 **Controlled human malaria infection as a tool for the development of novel malaria vaccine candidates**
B. Mordmüller, Tübingen

16:50
ST 19 **Malaria co-infections: a diagnostic challenge in malaria endemic regions of sub-Sahara Africa**
D. Eibach, Hamburg

17:00
ST 20 **Etiology of fever in hospitalized Children in Gabon: preliminary results**
J. Fernandes, Tübingen

17:10
ST 21 **A randomized, controlled, double-blind, single-center phase 1 clinical trial to evaluate safety, tolerability, immunogenicity and efficacy of CAF01 and aluminum hydroxide as adjuvants for the malaria vaccine candidate GMZ2 in African volunteers**
U. Ateba Ngoa, Lambaréné (Gabon)

17:20
AT 7 **Chlorotonil A: A potent antimalarial macrolactone with a pronouced antibacterial activity**
T. Abou Fayad, Saarbrücken/Braunschweig

17:30 – 17:40	**DZIF Poster Awards**
Festsaal	
17:40 – 18:10	**DZIF Award Lecture**
Festsaal	
18:10 – 19:10	**Get Together with Wine and Cheese**

ST = Short Talk, AT = Academy Talk

09:00 – 10:00	**TTU Emerging Infections**
Festsaal	*Chairs: J. F. Drexler, Bonn* *A. Volz, Munich*
09:00 TTU Lecture 8	**rVSV-ZEBOV: Investigation of intrinsic immunity to the vaccine vector VSV and its Ebola GP insert** *J. Pötsch, Hamburg*
09:20 ST 22	**Potential target for broad spectrum antiviral drugs** *E. Acosta, Heidelberg*
09:30 ST 23	**Evidence for widespread infection of African bats with Crimean-Congo hemorrhagic fever-like viruses** *M. Müller, Bonn*
09:40 ST 24	**p53 regulates SARS-CoV replication via interaction of SUD and PLpro with E3 ubiquitin ligase RCHY1** *A. von Brunn, Munich*
09:50 ST 25	**Development of MVA-MERS-S for phase I clinical evaluation: A candidate vaccine against middle east respiratory syndrome coronavirus** *A. Volz, Munich*
10:00 – 10:30	**Coffee Break**
10:30 – 11:00	**Invited Lecture 3**
Festsaal	
10:30	**The critical importance of screen validation in drug discovery: the search for a new macrofilaricide** *S. Ward, Liverpool (United Kingdom)*

11:00 – 12:00	**TTU Novel Antiinfectives**
Festsaal	*Chairs: W. Barchet, Bonn* *N. Ziemert, Tübingen*
11:00 TTU Lecture 9	**Mechanism-of-action of the cyclic depsipeptide antibiotic telomycin** *J. Herrmann, Saarbrücken/Braunschweig*
11:20 ST 26	**Exploiting underexplored translation inhibitors and combinations thereof** *A. Berscheid, Tübingen*
11:30 ST 27	**Genome mining-guided drug discovery: new avenues to protease and proteasome inhibitors from bacterial sources** *L. Kaysser, Tübingen*
11:40 ST 28	**Development of new treatments against filariasis using antibiotics** *U. Klarmann-Schulz, Bonn*
11:50 ST 29	**Antimicrobial action of Corallopyronin A against Orientia tsutsugamushi in vitro and in vivo** *C. Keller, Hamburg*
12:00 – 12:10	**Closing Remarks**
Festsaal	

TI Forum

At the same time of the poster sessions, representatives of the DZIF Translational Infrastructures (TI) will present their services. Take advantage of the opportunity to find out how the TIs can support your research.

DZIF TIs:

- Product Development Unit
- Clinical Trial Unit
- African Partner Institutions
- Natural Compound Library
- Biobanking
- Bioinformatics Platform
- Pathogen Repository
- Epidemiology

The DZIF Academy will also present its programmes. The aim of the DZIF Academy is to educate and train the next generation of researchers in infectious diseases. Highly attractive educational programmes for students and postgraduates are fundamental for excellent basic, translational and clinican scientists.

Poster Sessions

Posters shall be prepared in DIN A 0 size (841 x 1189 mm), portrait format, in English language. The dimensions of the poster walls are 1m x 2m, material to fix the posters will be provided.

All posters should be mounted on Thursday, 24 November 2016 from 10:00 – 13:00. Please remove your poster after the congress on Saturday, 26 November 2016 from 12:00 – 13:00. It is not possible to send remaining posters back to you after the congress. Unfortunately remaining posters have to be disposed of.

Poster authors are kindly asked to be present at their posters during the poster sessions on Thursday, 24 November 2016, from 16:10 – 17:10 and on Friday, 25 November 2016, from 13:30 –14:30 for questions and discussion.

DZIF Poster Awards

The three best posters will be awarded with EUR 500,- each. The awards will be presented on Friday, 25 November 2016 from 17:30 – 17:40 in “Festsaal”. All potential awardees will be informed in time and are kindly asked to attend. Please check your poster board for notification as well as your e-mail account.

The prizes are kindly sponsored by the MSD SHARP & DOHME GMBH.

HIV

P 1
Imaging platform under enhanced biosafety conditions
V. Laketa, Heidelberg

P 2
HIV-1 infection increases the frequency of inflammatory slanDCs that produce high levels of IL-1
F. Ahmad, Hanover

P 3
Mi(cro)RNAs as clinically relevant host factors and target molecules in HIV-1 infection
R. Müller, Heidelberg

P 4
Env-specific IgG responses induced by identical and none-identical immunogen prime-boost vaccination strategies target different antigenic region.
C. Geldmacher, Munich

P 5
Functional inactivation of the HIV-1 provirus using AAV-delivered CRISPR/Cas
M. Nickl, Heidelberg

P 6
Is persistent HIV viremia still an ongoing problem of antiretroviral treatment?
D. Schmidt, Berlin

P 7
HIV-1 latency reversal and HIV-1 infection measured by a novel flow-based technique
G. Martrus, Hamburg

P 8
Efficient and Safe Genome Editing by AAV-mediated Delivery of HIV-1 LTR-specific Recombinase Brec1 into Human Hematopoietic Stem Cells
N. Beschorner, Hamburg

P 9
Assessment of the HIV-1 reservoir in CD4+ T cell populations (including regulatory T cells) by a novel Droplet Digital PCR based approach
J. Schulze zur Wiesch, Hamburg

P 10
Wuchereria bancrofti infection doubles HIV incidence in Southwest Tanzania; a prospective cohort study
I. Kroidl, Munich

P 11
Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results
A. Ritter, Munich

P 12
Implementing novel strategies for the analysis of B cell responses to infectious pathogens
C. Kreer, Cologne

P 13
Immune Pressure in HLA-B27+ Elite Controllers Leads to Higher Susceptibility of HIV to Interferon Mediated Restriction
P. Schommers, Cologne

P 14
Dual inhibition of the thioredoxin and glutathione antioxidant pathways selectively kills latently HIV-infected cells and shows HIV eradication potential
I. Shytaj, Heidelberg

P 15
Chimeric Antigen Receptor T Cells using Broadly Neutralizing Antibodies to Target HIV-1
H. Gruell, Cologne

P 16
Non-pathogenic HIV-infection in children: Impact of immune activation, immune exhaustion, broadly neutralising antibodies and viral reservoirs on disease progression
M. Muenchhoff, Munich

HEPATITIS

P 17
Prevalence and characteristics of RAVs in DAA-naïve and -experienced European patients
J. Dietz, Frankfurt am Main

P 18
Longitudinal changes in peripheral CD4+ regulatory T cells upon treatment of chronic hepatitis C with direct-acting antivirals
B. Langhans, Bonn

P 19
Region specific prevalence of serologic markers for hepatitis virus types A-E in refugees and asylum seekers in northern Germany in 2015
S. Hardtke, Hanover

P 20
Immunological imprints in different phases of chronic hepatitis B virus infection
M. Cornberg, Hanover

P 21
Apolipoprotein E likely contributes to a maturation step of infectious hepatitis C virus particles and interacts with viral envelope glycoproteins
R. Bartenschlager, Heidelberg

P 22
Reduzierte CD161+MAIT Zell Frequenzen in HCV und HIV/HCV Koinfektion
J. Eberhard, Hamburg

P 23
Expression of human Sec14L2 is not a reliable predictor of HCV replication fitness
R. Costa, Hanover

P 24
A cross-reactive monoclonal antibody raised against recombinant hepatitis E virus genotype 3 capsid antigen
R. Ulrich, Greifswald/Riems

P 25
A selective neddylation inhibitor Pevonedistat potently interferes with HBV infection
B. Qu, Heidelberg

P 26
Towards eradication? The treatment reality of hepatitis C infection in Germany, 2010 - 2015
R. Zimmermann, Berlin

P 27
HCV Resistance Profile Evolution in a GT1b, DAA-naïve Patient before, on and after Failing Triple DAA Therapy
S. Sierra, Cologne

P 28
Human adult liver stem cells generated from patient samples
N. Fekete-Drimusz, Hanover

P 29
Characterization of T cell responses after stopping HBV therapy with nucleos(t)ide analogues (NA) in HBeAg-negative patients
F. Rinker, Hanover

P 30
Viral escape mutation contributes to failure of the hepatitis delta virus-specific CD8 T cell response restricted by HLA-B*27
H. Karimzadeh, Munich/Essen

P 31
Development of new qRT-PCR and RNA in situ hybridisation assays to determine genomic and antigenomic HDV RNA levels in livers of HBV/HDV co-infected humanized mice
M. Lütgehetmann, Hamburg

P 32
Seroprevalence of hepatitis B, hepatitis C, human immunodeficiency virus and Treponema pallidum and co-infections among blood donors in Kyrgyzstan – a retrospective analysis of three years (2013 – 2015)
M. Akmatov, Hanover

P 33
RNAi-mediated suppression of viral and host proteins to restore Hepatitis B Virusspecific immunity and enhance the efficacy of therapeutic vaccination
T. Bunse, Munich

P 34
Geno2pheno[HCV] – A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents
P. Kalaghatgi, Saarbrücken

P 35
Induction of preS1-specific antibody responses in chronic HBV and HBV/HDV coinfected patients treated with the entry inhibitor Myrcludex B
K. Schöneweis, Heidelberg

P 36
Characterizing the HCV Neutralizing Antibody Response
L. Dold, Bonn

P 37
Exploring the long-term in vitro model for persistent HBV/HDV infection
Y. Ni, Heidelberg

P 38
A Novel Core Protein Allosteric Modulators has Multiple Effects on the HBV Life Cycle
C. Ko, Munich

HEALTHCARE-ASSOCIATED AND ANTIBIOTIC-RESISTANT BACTERIAL INFECTIONS

P 39
Molecular characterization of third generation cephalosporin-resistant Enterobacteriacae – results from the ATHOS prevalence study
A. Hamprecht, Cologne

P 40
Sensitizing Staphylococcus aureus to cationic antimicrobial peptides by MprFinhibiting monoclonal antibodies
C. Slavetinsky, Tübingen

P 41
Detection of predominant, novel broad host range IncP-6 plasmid harboring blaKPC-2 in untreated wastewater
Y. Yao, Giessen

P 42
ASA³P: An automatic and highly scalable pipeline for bacterial genome assembly, annotation and higher-level analyses
O. Schwengers, Giessen

P 43
Gender differences in antibiotic prescribing in the community: a systematic review and meta-analysis
E. Tacconelli, Tübingen

P 44
STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship
E. Tacconelli, Tübingen

P 45
Knowledge, attitude, and practice (KAP) of Gambian health practitioners towards antibiotic prescribing and microbiological testing – a cross-sectional survey
P. Chaw, Braunschweig

P 46
Correlation of antibiotic usage and Clostridium difficile infections in a German university hospital
A. Rohde, Berlin

P 47
Biosynthesis of capsular polysaccharides as target for antibiotics
M. Rausch, Bonn

P 48
Identification of the AI-2-binding protein in the Quorum Sensing system of Enterococcus faecalis
V. Riedl, Munich

P 49
Novel insights into the operon encoding the plasmid-mediated colistin resistance (mcr-1)
K. Gwozdzinski, Giessen

P 50
The mechanism of Listeriolysin O-induced microtubule-associated protein 1-light chain 3 (LC3) conversion in macrophages
J. Podziemski, Giessen

P 51
Infection Risk in Sterile Operative Procedures
E. Tacconelli, Tübingen

P 52
DHG-SagA glycoconjugate is a potential vaccine candidate to fight enterococcal infections
D. Laverde, Munich

P 53
Evaluation of a Pediatric Antibiotic Stewardship Program – a pre-post comparison
K. Kreitmeyr, Munich

P 54
The genomic landscape of E.coli in a urology department at a German university hospital: towards the development of a rapid point-of-care test system for bacterial resistance as a tool for antibiotic stewardship
M. Fritzenwanker, Giessen

P 55
Preclinical development of HY-133, a recombinant phage lysin for rapid decolonization of Staphylococcus aureus from nasal habitats
A. Peschel, Tübingen

GASTROINTESTINAL INFECTIONS

P 56
Helicobacter pylori induces the expression of bactericidal Reg proteins in the stomach
R. Mejias Luque, Munich

P 57
Identification of a novel compound inhibiting the Salmonella Type III Secretion System
I. Grin, Tübingen

P 58
Colonization with Clostridium difficile before and during in-hospital stay in high-risk groups: A SPECTRUM study analysis
P. Solbach, Hanover

P 59
Substantial decrease of Shiga toxin-mediated cytotoxicity by liposomal pectinderived neoglycolipids, and neoglycoproteins as potential Shiga toxin inhibitors
G. Pohlentz, Münster

P 60
Establishment and optimisation of a mouse model for EHEC- and Shiga toxinmediated pathogenesis
S. Mühlen, Braunschweig

P 61
Analyzing microbiota composition changes in a preclinical C57BL/6 mouse model of Pseudomonas aeruginosa colonization/infection
F. Hölzl, Tübingen

P 62
Type I interferon signaling impairs anti-oxidative stress responses in Salmonella Typhimurium-infected macrophages
N. Hos, Cologne

P 63
baiCD gene abundance in C. difficile-colonized and -non-colonized patients
P. Solbach, Hanover

INFECTIONS OF THE IMMUNOCOMPROMISED HOST

P 64
The DZIF Transplantation Cohort e.V.
D. Schindler, Munich

P 65
Longitudinal changes in respiratory tract microbiota as a prognostic marker of complication-free survival after lung transplantation: study design and analysis concept for a clinical cohort study
A. Karch, Braunschweig/Hanover

P 66
Characterization and purification of HLA-C*07-restricted Cytomegalovirus-specific CD8+ T cells
F. Schlott, Munich

P 67
LöwenKIDS: A birth cohort study on infections and the development of the immune system: Study design, recruitment and baseline data
H. Raupach-Rosin, Braunschweig

P 68
Screening for novel small chemical compounds blocking Herpesviruses Infection
G. Beauclair, Hanover

P 69
Overexpression of the endoplasmatic reticulum aminopeptidase ERAP1 represents a possible new immune evasion mechanism of human papillomavirus-induced malignancies
A. Riemer, Heidelberg

P 70
A high-throughput screening system for antivirals targeting the human cytomegalovirus alkaline nuclease
T. Potgieter, Hamburg

P 71
Establishment of a High-Throughput Screening Assay for the LMP1::TRAF6 complex
F. Giehler, Munich

P 72
AAV based replicon technology for detection and quantification of herpesvirus replication and drug resistance
S. Langer, Munich

P 73
Immune-regulation of human cytomegalovirus in the immunocompromised host
P. Kay-Fedorov, Hanover

P 74
Biomarkers of complicated and/or protracted Epstein-Barr virus-associated infectious mononucleosis – PILOT STUDY
U. Behrends, Munich

P 75
Development of an Epstein-Barr virus (EBV) epitope quality scoring system for clinical application
D. Adhikary, Munich

P 76
Infection with a Gaussia luciferase expressing HCMV strain and latency modeling by non-invasive optical imaging analyses in mice reconstituted with the human immune system
S. Theobald, Hanover

P 77
Candida reactive T cells for Diagnosis of Invasive Candida Infection
F. Koehler, Cologne

P 78
Lifestyle factors and the risk of respiratory tract infections in the context of a population-based epidemiological study in South-Baden
A. Nieters, Freiburg

P 79
Development and validation of novel immunomodulatory strategies against Epstein-Barr-Virus infection and lymphoma using mice fully humanized with cord blood CD34+ stem cells
S. Danisch, Hanover

P 80
Novel antibodies with clinical potential against viral infections in the immunocompromised host
E. Fiestas Cárcaba, Munich

P 81
Building a comprehensive TCR library for off-the-shelf adoptive cell therapy of posttransplant infections
M. Effenberger, Munich

P 82
Bioinformatics Analysis of Whole Exome Sequencing data identifies structural variants in immune compromised children
M. Rohlfs, Munich

TUBERCULOSIS

P 83
Corticosteroids abrogate cytotoxicity of Mycobacterium tuberculosis through MAPK phosphatase 1 – implications for host-directed therapies
J. Gräb, Cologne

P 84
Preliminary results of natural product screens targeting Mycobacterium tuberculosis
J. Rybniker, Cologne

P 85
Transmission of tuberculosis in Germany: a new visualization tool for monitoring and surveillance
L. Fiebig, Berlin

P 86
A promising new drug target: M. tuberculosis thioredoxin reductase inhibitors with activity on mycobacterial growth in infected macrophages.
O. Koch, Dortmund

P 87
Enhanced TB Laboratory diagnosis and treatment in resource-limited settings – The Lambaréné Experience
A. Alabi, Lambaréné (Gabon)

P 88
Implementation of multidrug resistance tuberculosis (MDR-TB) treatment in Gabon: Lessons learnt from the field
U. Ateba Ngoa, Lambaréné (Gabon)

P 89
Tuberculosis treatment outcome and drug resistance in Lambaréné, Gabon – a prospective cohort study
S. Bélard, Lambaréné (Gabon)

P 90
Fostering programmatic uptake and implementation of research data for improved TB control in Gabon
M. Massinga-Loembe, Lambaréné (Gabon)

P 91
Development of a Therapeutic Drug Monitoring Platform for Patients with MDR-TB
H. Karakose, Borstel

P 92
Transcriptomic biomarkers for tuberculosis: Evaluation of DOCK9, EPHA4, and NPC2 mRNA expression in peripheral blood
F. Pessler, Hanover

P 93
Mycobacterium tuberculosis transmission from patients with drug-resistant compared to drug-susceptible tuberculosis: A systematic review and meta-analysis
K. Kranzer, Borstel

P 94
Efficacy of BTZ043 in two mouse models of tuberculosis infection
K. Walter, Borstel

P 95
Whole genome based genotyping of Mycobacterium tuberculosis complex isolates using a standardised and easily expandable genome-wide MLST approach
T. Kohl, Borstel

MALARIA

P 96
Treatment of Chronic Asymptomatic Plasmodium falciparum Infection Does Not Increase the Risk of Clinical Malaria upon Reinfection
S. Portugal, Heidelberg

P 97
Assessing the prophylactic activity of a single dose of DSM265 in a controlled human malarial infection challenge by direct venous inoculation of Plasmodium falciparum sporozoites (PfSPZ)
B. Mordmüller, Tübingen

P 98
Towards efficient malaria vaccination – unraveling CD8+ T cell dynamics induced by immunization with attenuated parasites
R. Frank, Heidelberg

P 99
Diagnosis and identification of causes of severe febrile illnesses in hospitalized children, Nouna Burkina Faso
A. Souares, Heidelberg

P 100
SC83288, a novel clinical development candidate for the treatment of severe malaria
M. Duffey, Heidelberg

P 101
Protection from malaria by sickle cell and related haemoglobin variants
M. Lanzer, Heidelberg

P 102
Deciphering humoral immune responses to Plasmodium using high-density peptide microarrays
K. Heiss, Heidelberg

P 103
Co-diagnoses in hospitalised children – revealing the cause of admission in a malaria endemic area
R. Krumkamp, Hamburg

P 104
Human Parvovirus B19 and Plasmodium falciparum co-infection in febrile children from Ghana
B. Hogan, Hamburg

EMERGING INFECTIONS

P 105
Novel cell targeting L-ddBCNA antiviral inhibits autophagy in virus infected cells
J. Bugert, Munich

P 106
Network "Rat-borne pathogens": Searching for pathogen co-infections
R. Ulrich, Riems

P 107
Perceptions of Zika virus risk in Lower Saxony in 2016
M. Hoodgarzadeh, Braunschweig

P 108
Whole genome sequencing based taxonomy in emerging and infectious bacterial pathogens
S. Doijad, Giessen

P 109
Tick-borne encephalitis – an emerging viral infection in Germany
G. Dobler, Munich

P 110
Two different mechanisms of emergence of tick-borne encephalitis virus in Eastern Bavaria
G. Dobler, Munich

P 111
First detection of Hyalomma rufipes in Germany
L. Chitimia-Dobler, Munich

P 112
Population structure of Esbl resistant ST131 isolates and non ESBL ST131 isolates
H. Ghosh, Giessen

P 113
Emerging and zoonotic viruses from domestic livestock
C. Bächlein, Hanover

P 114
Synergistic effects of novel antivirals Cima 4 and cf2642 on Zika virus
J. Bugert, Munich

P 115
Potential of Cyclophilin A antagonists as pan-Coronavirus blockers
A. von Brunn, Munich

P 116
Neutralizing antibodies against MERS Coronavirus in Dromedary Camels, Pakistan, 2012-2015
A. Sieberg, Bonn

P 117
Evaluation of RAG1 mutations in an adult with combined immunodeficiency and progressive multifocal leukoencephalopathy
C. Schröder, Hanover

P 118
TriReg – A Study of Trichosporonosis
L. Durán Graeff, Cologne

P 119
Influenza A (H7N9) vaccine based on the recombinant measles virus vaccine platform
M. Mühlebach, Langen

P 120
Emerging zoonotic pathogens in wild birds in Germany
U. Ziegler, Riems

P 121
Investigating the human B cell response to the Ebolavirus glycoprotein
S. Ehrhardt, Cologne

NOVEL ANTIINFECTIVES

P 122
Uridylpeptide antibiotics targeting Pseudomonads
N. Hauck, Tübingen

P 123
Evaluation of pharmacodynamics of recombinant chimeric bacteriophage endolysin HY-133 against Staphylococcus aureus small-colony variants and wild types
N. Schleimer, Münster

P 124
Development of Corallopyronin A as an antibiotic: cost-efficient production process
S. Bouhired, Bonn

P 125
Unculturable microorganisms as source for antibiotic discovery platforms
H. Harms, Bonn

P 126
Isolation of "uncultured" myxobacteria: A potential source of promising antiinfectives
R. Garcia, Saabrücken

P 127
Development of Screening Systems for the Identification of Novel Antibiotics
W. Wohlleben, Tübingen

P 128
Screening of cyanobacteria extracts for inhibitory activity against the cysteine protease rhodesain of Trypanosoma brucei
T. Niedermeyer, Tübingen

P 129
Sensitizing Staphylococcus aureus to cationic anti-microbial peptides
A. Jorge, Tübingen

P 130
Metabolic rewiring of macrophages during inflammation reveals new intervention points
K. Hiller, Braunschweig

P 131
Safety and efficacy of REP 2139 monotherapy and subsequent combination therapy with pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV coinfection
A. Vaillant, Montreal (Canada)

P 132
Population genomics of the myxobacterium Sorangium cellulosum
U. Nübel, Braunschweig

P 133
Combinatorial and synergistic effects of antibiotically active natural products from fungi
P. Barac-Poponut, Bonn

P 134
Antibiotic Resistant Target Seeker (ARTS): A multi-factor approach for detecting novel antibiotic resistant targets
M. Alanjary, Tübingen

P 135
A systematic analysis platform to elucidate antibiotic mechanisms
A. Mueller, Bonn

P 136
Preclinical development of chelocardins
T. Lukezic, Saabrücken/Braunschweig

P 137
Production process of protective, humanized, anti-Staphylococcus aureus antibody for clinical studies
A. Klimka, Cologne

P 138
Characterization of Staphylococcus aureus antigen-specific antibodies and the application of their epitope-peptides as vaccines against MRSA
A. Nicolai, Cologne

P 139
Control of human cytomegalovirus infection by murine and human monocyte-derived dendritic cells
B. Kasmapour, Braunschweig

P 140
An aspirin derivate impairs replication of coronavirus and other respiratory viruses
C. Müller, Giessen

P 141
Increasing Plasmodium immunogenicity during liver stage infection via nucleic acid based adjuvants to induce protective CTL immunity against Malaria
A. Valencia Hernandez, Bonn

P 142
Bipalindromic concatemerizing oligodeoxynucleotides (bpcODN) with modified 3'-ends are potent agonists of the cytosolic DNA recognition pathway
V. Boehnert, Bonn

P 143
A molecular pattern in RNA secondary structure promotes pathogen discrimination by Toll-like receptors 7 and 8
T. Zillinger, Bonn

Please find an index of all authors in the Book of Abstract.

SPEAKERS, CHAIRS AND PRESENTING AUTHORS

Venue

Flora Köln
Am Botanischen Garten 1a
50735 Cologne, Germany
www.koelnkongress.de

Congress Organization

COCS GmbH – Congress Organisation C. Schäfer
Rosenheimer Str. 145c
81671 Munich, Germany
Phone: +49 (0)89 / 89 06 77 – 0
Fax: +49 (0)89 / 89 06 77 – 77
E-mail: felicitas.molnar@cocs.de
www.cocs.de

Opening Hours Registration Desk

Thursday, 24 November 2016	10:00 – 18:30
Friday, 25 November 2016	08:00 – 19:30
Saturday, 26 November 2016	08:00 – 12:30

Social Evening

Thursday, 24 November 2016, from 20:00
Brauhaus Sion
Unter Taschenmacher 5-7
50667 Cologne, Germany

A registration for the participation in the social evening is absolutely essential – The number of participants is limited. There will be no extra charge.

Certification

A certification of the Ärztekammer Nordrhein and of the ICME is requested.

Hotel

You can choose your favorite hotel in Cologne from a wide range of hotel offers. Please make your reservation either via internet or via phone:

HRS – Hotel Reservation Service
Phone: +49 (0)221 2077 600, Fax: +49 (0)221 2077 666
www.hrs.de

Please note that COCS GmbH is only acting as an intermediary and takes no responsibility. Rebooking or cancellation must be made directly with the hotel.

Employer authorization for participation

For the purposes of the FSA codex we kindly ask for clinicians/scientists as employed to obtain an authorization from your employer to participate in the conference if necessary. The congress is supported by pharmaceutical/medical companies. The sponsors have no influence on the scientific programme.
The special sponsor symposium is clearly marked.

Registration

Please register until 10 November 2016 via our website www.dzif-annual-meeting2016.de

The fee includes all visits to the lectures as well as the participation in the social evening on Thursday, 24 November 2016 and your ticket for the public transport KVB (Kölner Verkehrs-Betriebe GmbH).

After 10 November 2016 registration and payment is only possible at the conference office on-site in Cologne. You will receive your ticket for the public transport there as well.

Registration fee

Participation	EUR 80,-
Student*	free entry

*) Verification by fax to +49 (0)89/890677-77. Otherwise the full price will be charged.

Payment

Please indicate on your bank transfer „DZIF2016“ and the name of the participant. After 10 November 2016, payments can only be accepted on-site.

COCS GmbH
HypoVereinsbank Munich
IBAN: DE75 700202700039611554
BIC: HYVEDEMMXXX
Reference: „DZIF2016“ and name of the participant

Please note that we do not cover any bank charges.

After your registration you will receive a confirmation and payment request immediately.

Cancellation

For written cancellation until 10 November 2016 there will be a cancellation fee of EUR 30,-. After this closing date, no refund of the participation fee is possible.
Please contact Ms. Felicitas Molnar for cancellation via felicitas.molnar@cocs.de

Congress Ticket

Provided that registration and payment are received until 10 November 2016, your ticket for the public transport will be sent to you in advance.

From 24-26 November 2016 you may use the regional train and all buses, trams and metros within the fare zone1b.

We would like to thank the following companies very much for their support:

Gold Sponsor

MSD SHARP & DOHME GMBH, Haar
EUR 20.500,- Symposium / Advertisement / Poster prize
www.msd.de

Bronze Sponsor

Boehringer Ingelheim Animal Health GmbH,
Ingelheim am Rhein
EUR 2.000,- Advertisement
www.boehringer-ingelheim.de

Janssen-Cilag GmbH, Neuss
EUR 2.300,- Advertisement
www.janssen-cilag.de

MSD SHARP & DOHME GMBH

About MSD:
MSD is part of Merck & Co., Inc., headquartered in Kenilworth, NJ, USA – a global health care leader. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. Furthermore, MSD is aiming to enhance global health care and to improve access to health care through far-reaching health care policies, Programmes, and partnerships. In Germany, MSD is located in Haar, near Munich.

For more information, please contact MSD at:
phone +49 800 673 673 673
fax: +49 800 673 673 329
email: Infocenter@msd.de
internet: www.msd.de

Congress venue
Flora Köln
Am Botanischen Garten 1a
50735 Cologne, Germany
www.koelnkongress.de

Arrival by car
From the motorway crossing the Zoobrücke (bridge) follow the signposts in the direction of “Zoo/Flora”. After turning right into “Alter Stammheimer Weg”, you will see the Flora on the left.

From the city center drive along the Konrad-Adenauer-Ufer and then follow the signposts to “Zoo/Flora” as described above.

Parking
On the left-hand side from the Flora you will find a small car park in front of the Flora. Pass the Flora and turn left into “Im Botanischen Garten”.

Further car parks can be found below the Zoobrücke and in the car park „Zoo-Flora“. You can reach it via „Riehler Straße“ or „Niederländer Ufer“.

Arrival by rail
On arrival at Cologne Central take the tram 18 (=subway) to the stop “Zoo/Flora”.

Arrival by public transport
Take the tram 18 (=subway) or the bus line 140 to the stop “Zoo/Flora”.

Arrival by airplane
On arrival at the Airport Cologne/Bonn take the tram 3 or 19 to the stop „Cologne Central Station“. Change here to the tram 18 (=subway) until the “Zoo/Flora” stop.

WIR SIND INFIZIERT VON DER LEIDENSCHAFT

MENSCHEN MIT INFEKTIONSKRANKHEITEN ZU HELFEN.

MSD Antiinfektiva

www.msd-antiinfektiva.de

MSD



MSD engagiert sich seit nahezu 80 Jahren umfassend auf dem Gebiet der Antiinfektiva. Die Entwicklung innovativer Produkte hat dabei höchste Priorität. Ganz aktuell wurden die Ergebnisse der Phase-III-Studie eines Impfstoffes gegen Ebola von MSD präsentiert. Bereits seit 1987 verfolgt das weltweit am längsten laufende Medikamentenspenden-Programm MECTIZAN von MSD mit Erfolg die Ausrottung der Flussblindheit und der Elefantiasis in betroffenen Ländern wie z. B. Kolumbien, Ecuador und Mexiko. Trotz aller Erfolge sterben jährlich weltweit immer noch bis zu 15 Mio. Menschen an Infektionskrankheiten – verursacht durch Viren, Bakterien, Pilze und Parasiten. Ihnen zu helfen war und ist unser Antrieb.

Zulassungsdaten der Präparate beziehen sich auf Deutschland.
* Daten beziehen sich auf das Unternehmen Merck & Co., Inc., Kenilworth, N.J., USA.
# In Kooperation mit der Rutgers Universität.

MSD SHARP & DOHME GMBH, Lindenplatz 1, 85540 Haar

AINF-116869-0002 03/16